BPC-157 Half-Life: What the Pharmacokinetic Data Show

In the only detailed pharmacokinetic study of the peptide, the elimination half-life of unchanged BPC-157 was less than 30 minutes in rats and beagle dogs after intravenous (IV) and intramuscular (IM) administration. No validated human half-life exists. Any figure of 4 to 6 hours, or a precise “time in your system,” is not supported by controlled human data. This article covers the animal numbers, the difference between parent peptide and metabolites, what that means for study design, and how researchers handle lyophilized BPC-157 vials in the laboratory.

All products discussed here are sold for laboratory research only. They are not approved for human or veterinary use.

Neolabpeptides

Source BPC-157 for Lab Research

Explore research-grade BPC-157 supplied in lyophilized form, with third-party testing and a Certificate of Analysis for each product.

Visit Neolabpeptides

TL;DR

Unchanged BPC-157 had an elimination half-life under 30 minutes in rats and beagles (IV and IM, single and repeated dosing).
Plasma levels peaked within 9 minutes after IM dosing, and the parent compound was not detectable 4 hours after administration.
Metabolites can be detected in urine for days, so “half-life” and “detection window” are different measurements.
No human pharmacokinetic study supports a human half-life, washout time or dosing interval. Animal values cannot be converted.
For bench work, reconstitution and storage choices affect the concentration you actually test, so document them.

What the 2022 rat and beagle study measured
Why you see 4 to 6 hours quoted online
Half-life, metabolites and detection windows are different things
Short half-life does not equal short effect
Handling lyophilized BPC-157 in the laboratory
Our perspective
Sourcing BPC-157 for laboratory studies
Reporting BPC-157 pharmacokinetics correctly
FAQ
Sources

What the 2022 rat and beagle study measured

The reference dataset is a 2022 study in Frontiers in Pharmacology, indexed on PubMed Central as PMC9794587. The authors used a solid-phase synthesized BPC-157 and tested it in rats and beagle dogs. The design covered a single IV dose, single IM doses at three levels, and repeated IM administration.

Key findings from that paper:

Elimination half-life: under 30 minutes for the prototype (unchanged) peptide, in both species, across all designs.
Time to peak: plasma concentration peaked within 9 minutes after IM administration.
Doses tested: 20, 100 and 500 µg/kg in rats; 6, 30 and 150 µg/kg in beagles.
Linearity: the authors report linear pharmacokinetic behavior at all tested doses.
Detectability: the parent compound was not detected 4 hours after administration.
Excretion: using tritium-labeled peptide, the authors found that urine and bile were the main excretory routes.

Other reviews repeat the same number. A 2025 literature and patent review summarizes BPC-157 as rapidly degraded with an elimination half-life below 30 minutes. A 2025 systematic review abstract of 36 studies published from 1993 through 2025 reports the same figure, plus hepatic metabolism and renal clearance. These are summaries of the same underlying animal work, not independent human measurements.

Why the species and route qualifiers matter

The same rat and beagle paper reports that IM bioavailability was roughly 14 to 19% in rats and 45 to 51% in beagles. That is a threefold spread between two mammals given the same route. It is a direct warning against carrying animal values over to another species or another route, such as subcutaneous, oral or intranasal administration. None of those routes has a measured human concentration-time curve in the literature we reviewed.

Intramuscular bioavailability ranges in rats and beagles

Why you see 4 to 6 hours quoted online

Search results for this topic give conflicting numbers. Some clinic and supplement-retail pages quote a half-life of roughly 4 to 6 hours for subcutaneous use. Others say under 2 hours. The peer-reviewed pharmacokinetic work we found supports neither as a measured human value.

There are a few plausible reasons for the confusion:

Detection windows get relabeled as half-life. Metabolites are detectable for days, which is a different quantity (see below).
Animal data are quoted without the species. The under-30-minute figure comes from rats and beagles.
Marketing copy blends pharmacokinetics with pharmacodynamics. A compound can be gone from plasma while downstream signaling continues.

The 2025 systematic review in HSS Journal of BPC-157 in orthopedic sports medicine is explicit on this point. Its metabolism and elimination findings come from animal models, and it describes the evidence as preclinical with no established human pharmacokinetic basis for converting animal data into a washout, exposure or dosing schedule. The ACG systematic review likewise notes that BPC-157 has no FDA approval and that clinical safety data are insufficient to support a validated human half-life, exposure model or evidence-based dosing interval.

The practical conclusion for a researcher: cite the animal number with its species and route, and do not write a human figure into a protocol or a manuscript.

Half-life, metabolites and detection windows are different things

Three measurements are routinely confused.

Measurement	What it answers	What the literature supports for BPC-157
Elimination half-life of parent peptide	How fast intact BPC-157 falls in plasma	Under 30 minutes in rats and beagles (IV, IM)
Metabolite detection window	How long breakdown products can be found in urine	Reported as 4 to 5 days in analytical studies cited by the HSS Journal review
Duration of biological effect	How long downstream signaling or tissue response lasts	Not defined by half-life; a separate research question

The HSS Journal review cites analytical work reporting urinary detection of BPC-157 metabolites for 4 to 5 days, with detection limits below 0.1 ng/mL in one study and 0.03 to 0.11 ng/mL in another. Those are metabolite findings, not a human half-life of the intact peptide.

A 2023 UHPLC-HRMS study, developed for doping-control analysis, identified one novel and eight conventional metabolites in two in-vitro incubation models. It then built a urine method covering the parent peptide and five major metabolites. The reported quantitative range was 0.02 to 50 ng/mL, with recovery above 90%. Those figures describe assay performance, not pharmacokinetics.

What this means for assay design

An assay for intact BPC-157 and an assay for its metabolites can return very different answers from the same sample. If you are building or validating a method, write down:

the analyte (parent peptide, a named metabolite, or a panel);
the matrix (plasma, urine, tissue homogenate, in-vitro incubation);
the extraction method;
the calibration range and limit of detection;
the reference material, including its lot and Certificate of Analysis.

That last item matters more than it looks. If the reference standard is of unknown purity, your calibration curve inherits the error. Our guide to BPC-157 stability with CoA and HPLC verification walks through how to read those documents.

Short half-life does not equal short effect

In the animal literature, BPC-157 is studied for angiogenic, anti-inflammatory and tissue-repair signals that are investigated over days, even though the parent peptide is cleared within hours. The 2022 study shows rapid disappearance of measurable parent peptide from plasma. It does not show that every downstream tissue signal ends at 30 minutes. Half-life is therefore a poor proxy for duration of effect, and a poor basis for choosing sampling times in a pharmacodynamic experiment.

The reverse also holds. A short half-life does not by itself settle safety. A 2025 peer-reviewed comment in Pharmaceuticals cautions that rapid clearance leaves open questions about repeated or long-term exposure, including metabolite activity, immunogenicity and formulation effects. Those are separate research questions, and the same systematic reviews that report the half-life also stress that human clinical safety data are lacking.

For study design, this suggests:

Sample early. With peak plasma levels reported within 9 minutes after IM dosing in animals, sparse late time points will miss the curve entirely.
Include time points that capture metabolites if your question is about exposure rather than intact peptide.
Separate your pharmacokinetic endpoints from your tissue or cell-based endpoints, and report them separately.
State species, route and dose in every figure legend.

Handling lyophilized BPC-157 in the laboratory

Half-life in vivo is only part of the story. Before any experiment, the peptide has to be dissolved to a known concentration and kept intact. Lyophilized (freeze-dried) powder is the standard supply format because it is far more stable in storage and shipping than a solution. Once the peptide is in solution, degradation becomes a practical concern.

Reconstitution basics

Reconstitution means dissolving the powder in a solvent to produce a solution of known concentration. In research settings, bacteriostatic water is a common choice. The arithmetic is simple:

Concentration = peptide mass in the vial ÷ solvent volume added

Worked example: a 10 mg vial reconstituted with 2 mL of solvent gives 5 mg/mL. The same vial with 4 mL gives 2.5 mg/mL. Pick the volume that gives a stock you can dilute accurately to your working concentration without pipetting tiny volumes.

A reasonable bench routine looks like this:

Bring the sealed vial to room temperature before opening so condensation does not enter the powder.
Wipe the stopper with an alcohol swab and let it dry.
Calculate the target concentration and the solvent volume before you start, and write both down.
Add the solvent slowly down the inner wall of the vial rather than directly onto the cake.
Swirl gently until clear. Avoid vigorous shaking, which can cause foaming and aggregation in some peptides.
Label the vial with concentration, solvent, date and lot number.
Store according to your protocol and the supplier’s guidance, and avoid repeated freeze-thaw cycles by preparing aliquots where your design allows.

This is a general laboratory outline for in-vitro and analytical work. Follow your institution’s chemical hygiene plan and any protocol approved by your institutional committee. Questions about specific stability windows for reconstituted material should be settled empirically, for example by re-running HPLC on a stored aliquot, rather than assumed.

Verify what is in the vial

Reconstitution math assumes the label is right. Two documents tell you whether it is:

HPLC chromatogram showing purity, typically reported as a percentage of the main peak.
Mass spectrometry confirming the molecular identity of that peak.

A Certificate of Analysis should be tied to the specific lot you are using. For a deeper look at how the two methods differ, see our comparison of TB-500 and BPC-157 purity verification, and for building an in-house check, the peptide testing kit guide for researchers.

Our perspective

We supply research-grade peptides, and half-life questions reach us from people who want a single number. The honest answer is a qualified one. The best-documented figure is under 30 minutes for the unchanged peptide in rats and beagles, and everything beyond that is either a metabolite finding or an extrapolation.

What we can control is the quality of the material that goes into your experiment. Every product is independently tested for purity and identity, with third-party Certificates of Analysis published per lot, and we ship cold-chain from US facilities to verified researchers. If a pharmacokinetic result looks odd, the first thing worth checking is the reference material, because an under-dosed or impure vial produces a curve that says more about the vial than the compound.

We would also rather a researcher cite a number correctly than cite a bigger one. A clean statement of species, route and analyte is more useful to your reviewers than a human half-life that no study has measured. Our own summaries of the field, what the evidence actually supports and mechanisms and pre-clinical findings, follow the same rule.

— Stephan

Sourcing BPC-157 for laboratory studies

If your protocol calls for BPC-157 reference material, the BPC-157 10mg research peptide is supplied as a lyophilized powder with a Certificate of Analysis, verified at 98%+ purity by HPLC and mass spectrometry. Related compounds, including blends and bacteriostatic water, are listed under Healing & Recovery. Shipping terms and returns are on the Shipping & Returns page. Products are for laboratory research only and are sold to verified researchers.

Reporting BPC-157 pharmacokinetics correctly

A short checklist for manuscripts, grant text and internal protocols:

Write “elimination half-life of unchanged BPC-157 below 30 minutes in rats and beagle dogs after IV and IM administration,” with a citation to the primary study.
Do not use the phrase “human half-life” unless you are reporting your own controlled human data.
Do not describe urinary metabolite detection as persistence of the intact peptide.
Name the assay, matrix, calibration range and limit of detection.
Record the supplier, lot number and CoA for every vial.
Note that the available evidence base is predominantly preclinical, as the 2025 reviews state.

FAQ

What is the half-life of BPC-157?

In rats and beagle dogs, the elimination half-life of unchanged BPC-157 was under 30 minutes after IV and IM administration. No validated human half-life has been established. Figures such as 4 to 6 hours circulate online but are not backed by a controlled human pharmacokinetic study.

How long does BPC-157 stay detectable?

The parent peptide was not detectable 4 hours after administration in the rat and beagle study. Metabolites are a different matter: analytical studies cited in a 2025 systematic review report urinary metabolite detection for 4 to 5 days. These findings come from animal and analytical work, so they should not be read as a human washout time.

Does a short half-life mean the effect is short?

Not necessarily. Half-life describes how fast the intact peptide leaves plasma, while biological responses in tissue are studied over longer periods in the animal literature. Half-life should not be used as a stand-in for duration of effect, and it does not resolve safety questions about repeated exposure.

How do I calculate concentration when reconstituting a lyophilized BPC-157 vial?

Divide the peptide mass in the vial by the solvent volume you add. A 10 mg vial dissolved in 2 mL gives 5 mg/mL, and in 4 mL gives 2.5 mg/mL. Record the solvent, volume, date and lot number on the vial, and confirm stability of stored solutions with your own analytical checks.

Is BPC-157 approved by the FDA?

As of the 2025 systematic review, BPC-157 has no FDA approval, and clinical safety data are insufficient to support a human exposure model or dosing interval. Neo Lab Peptides sells it strictly for laboratory research, not for human or veterinary use.